_______________________________________________________________________________________________________________
OXB stronger links between sites and creating a manufacturing network that supports customers in every region.
Acquiring facilities in Lyon and Strasbourg was part of that effort. The goal was not just to add more space, but to establish key platforms across continental Europe and reduce reliance on a single location. Now, Lyon handles development and GMP-scale work for lentiviral and AAV programs.
With activity in Strasbourg and Oxford too, these facilities have helped create a network that gives customers access to the same capabilities in multiple locations. Building that network took more than physical sites. It required consistency.
Historically, process characterization capabilities sat primarily within the UK operation. As OXB expanded, customers increasingly wanted access to this expertise elsewhere in the network, as Sébastien explains.“ Over the past 18 months, we’ ve established a process characterization
blueprint across all of our sites, giving customers access to the same capabilities across multiple geographies rather than relying on a single location.”
The result has been greater flexibility for customers and a different way of approaching timelines.“ We’ re currently supporting two customers by running process characterization activities in parallel across two sites.” The focus on time has become increasingly important as therapies move through development. Sponsors are under pressure to reach clinical milestones more quickly, and they want manufacturers to compress schedules.
Sébastien notes that rather than treating the timelines as fixed, OXB has challenged some of the assumptions behind them.“ We’ re delivering material for Phase I programs in seven to nine months for both vector types, compared with the typical 12 to 18 months seen across the industry.”
The fast-track strategies developed for
manufacturing-today. com 123